Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442592 | 0.85 | KMT2A (0.74) | KMT2AOPRM1OPRL1OPRD1PDE4A | |
| SCHEMBL4872137 | 0.81 | OPRM1 (0.70) | KMT2AOPRM1OPRL1OPRD1ALDH1A1 | |
| SCHEMBL11814914 | 0.81 | KMT2A (1.00) | KMT2AOPRM1 | |
| SCHEMBL1007128 | 0.80 | KMT2A (0.78) | KMT2AOPRM1OPRL1OPRD1ALDH1A1 | |
| SCHEMBL8260621 | 0.80 | KMT2A (0.74) | KMT2AOPRM1OPRL1OPRD1PDE4A | |
| Hydrochloric Acid SCHEMBL8355555 | 0.80 | OPRM1 (0.68) | KMT2AOPRM1OPRL1ALDH1A1 | |
| SCHEMBL4872645 | 0.78 | OPRD1 (0.56) | KMT2AOPRM1OPRL1OPRD1ALDH1A1 | |
| SCHEMBL7387709 | 0.78 | KMT2A (0.74) | KMT2AOPRM1OPRD1ALDH1A1OPRK1 | |
| SCHEMBL7539835 | 0.78 | KMT2A (0.74) | KMT2AOPRM1OPRD1ALDH1A1OPRK1 | |
| SCHEMBL4878341 | 0.77 | OPRM1 (0.57) | KMT2AOPRM1OPRD1ALDH1A1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | KMT2A 1132/4885OPRM1 1290/4885OPRL1 1078/4885 |
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | KMT2A 1301/4885OPRM1 211/4885OPRL1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.